Bank of New York Mellon Corp raised its stake in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 3.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,733 shares of the biopharmaceutical company’s stock after acquiring an additional 6,169 shares during the period. Bank of New York Mellon Corp owned approximately 0.37% of Agios Pharmaceuticals worth $17,918,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the company. Woodford Investment Management Ltd bought a new stake in Agios Pharmaceuticals during the 2nd quarter worth $32,849,000. Wells Fargo & Company MN grew its position in Agios Pharmaceuticals by 459.8% during the 2nd quarter. Wells Fargo & Company MN now owns 407,393 shares of the biopharmaceutical company’s stock worth $34,315,000 after acquiring an additional 334,617 shares during the last quarter. Castleark Management LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter worth $8,114,000. First Trust Advisors LP grew its position in Agios Pharmaceuticals by 8.3% during the 2nd quarter. First Trust Advisors LP now owns 731,794 shares of the biopharmaceutical company’s stock worth $61,639,000 after acquiring an additional 56,038 shares during the last quarter. Finally, BlackRock Inc. grew its position in Agios Pharmaceuticals by 1.3% during the 2nd quarter. BlackRock Inc. now owns 3,248,251 shares of the biopharmaceutical company’s stock worth $273,601,000 after acquiring an additional 42,198 shares during the last quarter. 94.93% of the stock is owned by institutional investors.
In other Agios Pharmaceuticals news, Director John Maraganore sold 13,555 shares of the company’s stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $72.75, for a total value of $986,126.25. Following the sale, the director now owns 38,609 shares in the company, valued at approximately $2,808,804.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Scott Biller sold 3,000 shares of the company’s stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $83.07, for a total value of $249,210.00. Following the completion of the sale, the insider now owns 60,196 shares in the company, valued at approximately $5,000,481.72. The disclosure for this sale can be found here. Insiders sold a total of 22,555 shares of company stock worth $1,653,776 in the last quarter. Corporate insiders own 3.02% of the company’s stock.
AGIO has been the topic of a number of research reports. BidaskClub lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, October 6th. Cowen restated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Friday, November 2nd. Oppenheimer restated a “hold” rating on shares of Agios Pharmaceuticals in a research report on Thursday, November 1st. Cann restated a “hold” rating on shares of Agios Pharmaceuticals in a research report on Friday, November 16th. Finally, Leerink Swann initiated coverage on Agios Pharmaceuticals in a research report on Monday, September 24th. They set a “market perform” rating and a $80.00 price objective on the stock. Six analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Agios Pharmaceuticals presently has an average rating of “Buy” and an average price target of $96.27.
NASDAQ AGIO opened at $65.80 on Monday. Agios Pharmaceuticals Inc has a 12 month low of $51.62 and a 12 month high of $99.82. The stock has a market capitalization of $3.83 billion, a price-to-earnings ratio of -9.75 and a beta of 2.04.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.01). Agios Pharmaceuticals had a negative net margin of 461.78% and a negative return on equity of 48.51%. The company had revenue of $15.20 million during the quarter, compared to the consensus estimate of $22.72 million. During the same quarter last year, the firm posted ($1.59) EPS. The company’s quarterly revenue was up 33.8% on a year-over-year basis. On average, equities research analysts expect that Agios Pharmaceuticals Inc will post -6.12 earnings per share for the current fiscal year.
Agios Pharmaceuticals Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Featured Article: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.